3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Interventions
pembrolizumab
14
Nivolumab
9
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
fludarabine
3
atezolizumab
3
Ipilimumab
3
Drug Therapy
3
Cyclophosphamide
3
epacadostat
2
entrectinib
2
durvalumab
2
X-Rays
2
Sirolimus
2
Radiotherapy
2
Radiation
2
Methods
2
Interleukin-2
2
Injections
2
CTLA-4 Antigen
2
Blood Specimen Collection
2
Biopsy
2
zimberelimab
1
vocimagene amiretrorepvec
1
varlilumab
1
utomilumab
1
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
GSK-3326595
×
Lymphoid
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts